{
    "clinical_study": {
        "@rank": "111056", 
        "arm_group": [
            {
                "arm_group_label": "Test Treatment 1: BI 1026706", 
                "arm_group_type": "Experimental", 
                "description": "BI 1026706 plus matching placebo to BI 1026706 Powder for Oral Solution (PfOS) and placebo tablet"
            }, 
            {
                "arm_group_label": "Test Treatment 2: BI 1026706", 
                "arm_group_type": "Experimental", 
                "description": "BI 1026706 and placebo tablet"
            }, 
            {
                "arm_group_label": "Reference Treatment 1: BI 1026706", 
                "arm_group_type": "Experimental", 
                "description": "Matching placebo to BI 1026706 PfOS and placebo tablet"
            }, 
            {
                "arm_group_label": "Reference Treatment 2: Celecoxib", 
                "arm_group_type": "Experimental", 
                "description": "Celecoxib hard capsule as active comparator plus matching placebo to BI 1026706 PfOS"
            }, 
            {
                "arm_group_label": "Reference Treatment 3: Pregabalin", 
                "arm_group_type": "Experimental", 
                "description": "Pregabalin hard capsule as active comparator plus matching placebo to BI 1026706 PfOS"
            }
        ], 
        "brief_summary": {
            "textblock": "-  To investigate the influence of different doses of BI 1026706 on the primary endpoint\n           (PtP-amplitude LEP in UV skin) compared to placebo.\n\n        -  The comparison of both doses of BI 1026706 to celecoxib in the UVB treatment.\n\n        -  Comparison of both doses of BI 1026706 to placebo and pregabalin in the capsaicin\n           treatment\n\n        -  Exploration of the pharmacokinetics of BI 1026706\n\n        -  Exploration of safety and tolerability of BI 1026706"
        }, 
        "brief_title": "Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB(Ultraviolet)-Irradiated Skin in Healthy Male Volunteers", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Healthy males according to the investigator's assessment, as based on the following\n             criteria: a complete medical history including a physical examination, vital signs\n             (Blood Pressure, Pulse Rate), 12-lead electrocardiogram, and clinical laboratory\n\n          2. Age 18 to 55 years (incl.)\n\n          3. BMI (Body Mass Index) 18.5 to 29.9 kg/m2 (incl.)\n\n          4. Signed and dated written informed consent prior to admission to the study in\n             accordance with GCP and local legislation\n\n        Exclusion criteria:\n\n          1. Any finding in the medical examination (including Blood Pressure, Pulse Rate or\n             Electrocardiogram) deviating from normal and judged clinically relevant by the\n             investigator\n\n          2. Repeated measurement of systolic blood pressure greater than 140 mm Hg or diastolic\n             blood pressure greater than 90 mm Hg\n\n          3. Any laboratory value outside the reference range that the investigator considers to\n             be of clinical relevance\n\n          4. Any evidence of a concomitant disease judged clinically relevant by the investigator\n\n          5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,\n             immunological or hormonal disorders\n\n          6. Surgery of the gastrointestinal tract that could interfere with kinetics of the study\n             drug(s)\n\n          7. Diseases of the central nervous system (such as epilepsy), other neurological\n             disorders or psychiatric disorders"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02037165", 
            "org_study_id": "1320.3", 
            "secondary_id": "2012-005691-33"
        }, 
        "intervention": [
            {
                "arm_group_label": "Test Treatment 2: BI 1026706", 
                "description": "Placebo tablet", 
                "intervention_name": "Placebo to BI 1026706", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Reference Treatment 2: Celecoxib", 
                "description": "Placebo oral solution", 
                "intervention_name": "Placebo to BI 1026706", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Reference Treatment 3: Pregabalin", 
                "description": "Pregabalin hard capsule", 
                "intervention_name": "Pregabalin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Test Treatment 1: BI 1026706", 
                "description": "Placebo oral solution", 
                "intervention_name": "Placebo to BI 1026706", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Reference Treatment 3: Pregabalin", 
                "description": "Placebo oral solution", 
                "intervention_name": "Placebo to BI 1026706", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Test Treatment 1: BI 1026706", 
                "description": "Placebo tablet", 
                "intervention_name": "Placebo to BI 1026706", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Reference Treatment 1: BI 1026706", 
                "description": "Placebo tablet", 
                "intervention_name": "Placebo to BI 1026706", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Test Treatment 1: BI 1026706", 
                "description": "BI 1026706 oral solution", 
                "intervention_name": "BI 1026706", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Test Treatment 2: BI 1026706", 
                "description": "BI 1026706 oral solution", 
                "intervention_name": "BI 1026706", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Reference Treatment 1: BI 1026706", 
                "description": "Placebo oral solution", 
                "intervention_name": "Placebo to BI 1026706", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Reference Treatment 2: Celecoxib", 
                "description": "Celecoxib hard capsule", 
                "intervention_name": "Celecoxib", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pregabalin", 
                "Celecoxib"
            ]
        }, 
        "lastchanged_date": "April 30, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dornach", 
                    "country": "Germany"
                }, 
                "name": "1320.3.1 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "5", 
        "official_title": "Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB (Ultraviolet)-Irradiated Skin in Healthy Male Volunteers (a Single-blinded, Randomised, Placebo-controlled, Single-dose, Five-way Crossover Study)", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Overall Peak-to-Peak (PtP) N2/P2-component amplitude of Laser (somatosensory/radiant heat) evoked potentials (LEP) [\u00b5V] in UVB-irradiated skin", 
            "safety_issue": "No", 
            "time_frame": "up to 24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02037165"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall Peak-to-Peak (PtP) N2/P2-component amplitude of (LEP) [\u00b5V] in capsaicin-irritated skin", 
                "safety_issue": "No", 
                "time_frame": "up to 24 hours"
            }, 
            {
                "measure": "Single \"peripheral\" (N2) component amplitudes [\u00b5V] - measured in both treated skin types", 
                "safety_issue": "No", 
                "time_frame": "up to 24 hours"
            }, 
            {
                "measure": "Single \"central\" (P2) component amplitudes [\u00b5V] - measured in both treated skin types", 
                "safety_issue": "No", 
                "time_frame": "up to 24 hours"
            }, 
            {
                "measure": "Electronic Visual Analogue Scale (100mm VAS \"Post Laser Pain\" scales) - measured in the two different skin types", 
                "safety_issue": "No", 
                "time_frame": "up to 24 hours"
            }, 
            {
                "measure": "Weighted needle (pain) threshold (WNT) the secondary capsaicin flare area", 
                "safety_issue": "No", 
                "time_frame": "up to 24 hours"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}